Bastide Le Confort Médical SA (BLC)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 17.92 |
|---|---|
| 52-week range | 17.56 – 27.50 |
| Return, 1 month / 3 months | −17.4% / −22.6% |
| Return, 1 year / 3 years | −24.9% / −14.1% |
| Trend | Below its 200-day average |
| RSI (14) | 38 |
| Volatility (1 year) | 35.4% |
| Worst drawdown (1 year) | -35.8% |
| Average daily value traded | 0.06M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bastide Le Confort Médical is a French provider of home healthcare services and medical equipment. The company supplies respiratory assistance, oxygen therapy, infusion and nutrition services, and it rents out equipment such as beds, wheelchairs and oxygen concentrators to patients in their homes. It also operates a network of pharmacies and home-care branches, serving patients, hospitals and healthcare professionals mainly in France and other parts of Europe. The company is based in Caissargues, in southern France.
Bastide Le Confort Médical SA trades under the code BLC on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bastide Le Confort Médical SA (BLC) trades on the Euronext Paris in France. It last closed at EUR 17.92 on 19 October 2026.
Its price-based Market X-Ray is 40 out of 100 (a weak price profile), ranking 429 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 24.9% and over the last three months it fell 22.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 29 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -24.0% | ||
| From 52-week high | -34.7% | ||
| Momentum | 29 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -22.6% | ||
| 6-month return | -28.0% | ||
| 12-month return, skipping the last month | -9.0% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 35.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -35.8% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.06M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −8.0% |
|---|---|
| 1 month | −17.4% |
| 3 months | −22.6% |
| 6 months | −28.0% |
| 1 year | −24.9% |
| 3 years | −14.1% |
| 5 years | −58.5% |
Signals
| 50-day / 200-day average | 21.09 / 23.57 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.76 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 7 Jan 2022 | EUR 0.2700 |
| 7 Jan 2021 | EUR 0.2700 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.